Skip to main content
. Author manuscript; available in PMC: 2014 Apr 4.
Published in final edited form as: Metab Brain Dis. 2014 Mar;29(1):37–45. doi: 10.1007/s11011-013-9440-0

Fig. 5.

Fig. 5

DRα1-MOG-35-55 treatment increases the frequency of activated CD4+ cells but does not change the activation state of CD11b+ cells in the spleen 96 h after MCAO. a CD11b+ cells in the spleen of DRα1-MOG-35-55-treated (n =10) versus Vehicle-treated mice (n =12) were analyzed for the expression of CD80, HLA MHC class II, ICAM-1 and CCR2. b CD4+ cells in spleen were analyzed for the expression of CD44 and CD62L. Data are presented as mean ± SEM. * p <0.05, Student’s t-test